SCHEMBL4665847

SCHEMBL4665847

O=S(=O)(Nc1ccc(Nc2cc(-c3cccc(OCCN4CCOCC4)c3)ncn2)cc1)c1ccccc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 4/20 0.51
BCR P11274 4/20 0.51
EPHX2 P34913 3/20 0.43
RET P07949 1/20 0.42
JAK1 P23458 4/20 0.42
JAK3 P52333 4/20 0.42
JAK2 O60674 3/20 0.42
FLT3 P36888 1/20 0.41
PIK3R1 P27986 1/20 0.41
PIK3CA P42336 1/20 0.41
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
MET P08581 1/20 0.40
AXL P30530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663979 0.96 ABL1 (0.50) ABL1BCREPHX2JAK1JAK3
SCHEMBL4665778 0.92 ABL1 (0.49) ABL1BCREPHX2RETPIK3R1
SCHEMBL4663917 0.92 ABL1 (0.48) ABL1BCRRETJAK1JAK3
SCHEMBL4665820 0.88 ABL1 (0.48) ABL1BCREPHX2METAXL
SCHEMBL4667480 0.88 ABL1 (0.51) ABL1BCREPHX2JAK1JAK3
SCHEMBL4665836 0.88 AXL (0.48) ABL1BCRUSP2CYP1A2CYP3A4
SCHEMBL4665611 0.85 ABL1 (0.49) ABL1BCREPHX2RETJAK1
SCHEMBL4664349 0.85 ABL1 (0.51) ABL1BCRJAK1JAK3JAK2
SCHEMBL4663820 0.83 ABL1 (0.47) ABL1BCRAXL
SCHEMBL4664345 0.83 SRC (0.43) ABL1BCRUSP2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 ABL1 24/4885BCR 402/4885EPHX2 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.